United States v. Eric Opitz

704 F. App'x 66
CourtCourt of Appeals for the Third Circuit
DecidedAugust 8, 2017
Docket17-1322
StatusUnpublished
Cited by1 cases

This text of 704 F. App'x 66 (United States v. Eric Opitz) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Eric Opitz, 704 F. App'x 66 (3d Cir. 2017).

Opinion

OPINION *

SHWARTZ, Circuit Judge.

Eric Opitz appeals two aspects of his sentence: the loss calculation under the United States Sentencing Guidelines and the restitution order. Because the District Court’s loss calculation was supported by the evidence and the Court did not commit plain error in imposing restitution for the losses that resulted from Opitz’s crimes, we will affirm.

I

Opitz suffers from human growth hormone deficiency and received a prescription for Genotropin, a human growth hormone supplement. Medicare paid for Opitz’s Genotropin at a cost of approximately $461 per kit. From July 2012 through June 2014, Opitz sold the Geno-tropin for approximately $425 per kit, using postings on Craigslist. Undercover agents contacted Opitz through a Craig-slist advertisement and purchased Geno-tropin from him. In addition, law enforcement identified more than twenty people who purchased the drug from Op-itz.

A grand jury returned a twenty-count indictment charging Opitz with health care fraud, in violation of 18 U.S.C. § 1347 (Counts 1-10); mail fraud, in violation of 18 *68 U.S.C. § 1341 (Counts 11-13); distribution of human growth hormone, in violation of 21 U.S.C. § 333(e) (Counts 14-17); and distribution of controlled substances in violation of 21 U.S.C. § 841 (Counts 18-20). Opitz pled guilty to all of the charges in the indictment without a plea agreement.

At the sentencing hearing, the District Court considered evidence of the loss sustained as a result of Optiz’s health care fraud. App. 17. The Government argued that a loss figure totaling $171,353 was appropriate because it was at least, if not less than, the amount Medicare paid for the Genotropin Opitz admitted he fraudulently obtained, as reflected by his plea to Counts One through Ten of the indictment. The Government asserted that this was a reasonable figure because Opitz had not revealed to Medicare his intention to sell some of the drugs and thus he had received all of the drugs from Medicare under a false pretense. The Government also presented evidence from Opitz’s bank account showing cash deposits totaling $97,760, which, it said, included approximately $33,000 in wire transfers from his customers, 1 records from the Sands Casino in Bethlehem indicating Opitz made over $400,000 in buy-ins, handwritten notes taken from Opitz’s residence showing the contact information for Genotropin customers and calculations for past sales, 2 and his posting on Craigslist of over 1,800 advertisements offering to sell Genotropin. 3 Op-itz argued that while he was guilty of selling Genotropin, he used most of the drugs himself and should be responsible only for the value of the drugs that the Government proved he resold, which totaled $46,514.

In addressing the loss calculation under the Guidelines, the District Court found that the evidence supported the Government’s proposed intended loss calculation of approximately $171,000. Applying the grouping rules, Opitz faced a Guidelines range of fifteen to twenty-one months. The Court imposed a sentence of eighteen months’ imprisonment followed by three years of supervised release, and ordered Opitz to pay a special assessment of $2,000 and restitution of $171,353 to Medicare. Although Opitz objected to the Guideline loss calculation, he did not object to the restitution order. Opitz appeals.

II 4

Opitz now challenges both the District Court’s loss calculation and restitution order. We will address each in turn.

A 5

The burden of proving the loss amount at sentencing rests with the Government. United States v. Evans, 155 F.3d 245, 253 (3d Cir. 1998); United States v. McDowell, 888 F.2d 285, 291 (3d Cir. 1989). “[O]nce the Government makes out a prima facie case of the loss amount, the burden of production shifts to the defendant to provide evidence that the Government’s evi *69 dence is incomplete or inaccurate.” United States v. Jimenez, 513 F.3d 62, 86 (3d Cir. 2008).

Opitz was convicted of, among other things, violations of 18 U.S.C. § 1347, which is a “federal health care fraud offense.” 18 U.S.C. § 24(a)(1); U.S. Sentencing Guidelines Manual § 2B1.1 cmt. n.1 (U.S. Sentencing Comm’n 2016) (“USSG”). The applicable Guideline for this offense is set forth in U.S.S.G. § 2B1.1 and, because the offense involved a government health care program, it is subject to a special rule for calculating the loss amount. See, e.g., id. at § 2B1.1 cmt. n.3(F)(viii); United States v. Popov, 742 F.3d 911, 916 (9th Cir. 2014). 6 That rule provides that

[i]n a case in which the defendant is convicted of a Federal health care offense involving a Government health care program, the aggregate dollar amount of fraudulent bills submitted to the Government health care program shall constitute prima facie evidence of the amount of the intended loss, i. e., is evidence sufficient to establish the amount of the intended loss, if not rebutted.

U.S.S.G. § 2B1.1 cmt. n.3(F)(viii). Under this special rule, therefore, the amount billed to Medicare is prima facie evidence of intended loss and, if not rebutted is sufficient to establish the loss amount by a preponderance of the evidence. 7 Popov, 742 F.3d at 916.

Opitz pled guilty to submitting fraudulent claims totaling $171,353 to Medicare. As a result of this plea, the Government has presented prima facie evidence that the intended loss amount was $171,353. Although Opitz argued that the loss amount should be reduced because he used some of the Genotropin himself, he only presented evidence that he had a condition for which human growth hormone was prescribed. While the District Court accepted Opitz’s assertion that he took a certain amount of human growth hormone during the relevant period, despite his statements to an undercover agent that his doctor took him off the prescription, he provided no evidence from which that amount could be calculated. Thus, Opitz did not rebut the loss amount. Accordingly, Opitz’s assertion that the District Court incorrectly calculated the loss amount is without merit.

B

Free access — add to your briefcase to read the full text and ask questions with AI

Related

PATEL v. United States
D. New Jersey, 2022

Cite This Page — Counsel Stack

Bluebook (online)
704 F. App'x 66, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-eric-opitz-ca3-2017.